<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
<channel>
<title/>
<link>http://repo.tma.uz/xmlui/handle/1/2546</link>
<description/>
<pubDate>Tue, 20 Oct 2026 16:10:58 GMT</pubDate>
<dc:date>2026-10-20T16:10:58Z</dc:date>
<item>
<title>FEATURES OF THE CLINICAL COURSE AND EFFICIENCY OF HYPOURICEMIC  THERAPY OF GOUT IN FEMALE DEPENDING ON GENE POLYMORPHISM</title>
<link>http://repo.tma.uz/xmlui/handle/1/5544</link>
<description>FEATURES OF THE CLINICAL COURSE AND EFFICIENCY OF HYPOURICEMIC  THERAPY OF GOUT IN FEMALE DEPENDING ON GENE POLYMORPHISM
Nabieva D.A.1., Tashpulatova M.M., Djurayeva E.R.3., Ziyayeva F.K.4.,  Matchanov S.X.5., Abdurazzoqova D.S.6
The article presents modern data on the influence of the most common polymorphisms APEX1 &#13;
T444G and ABCG2 C421A RS2231142 of genes encoding proteins that are involved in the renal urate &#13;
transport system and, thus, associated with the level of uric acid or gout. Characterization of &#13;
polymorphisms APEX1 T444G and ABCG2 C421A RS2231142 of genes: V253I, Q126X, Q141K was &#13;
carried out. It was determined that the GCA and GTC haplotypes of the Q126X and Q141K &#13;
polymorphisms can be predictors of gout. The interrelation of APEX1 T444G and ABCG2 C421A &#13;
RS2231142 gene polymorphisms with the presence of hyperuricemia depending on gender, &#13;
components of metabolic syndrome, and response to allopurinol was analyzed. Most genes associated &#13;
with MK or gout in a genome-wide association study encode proteins that are involved in the renal &#13;
urate transport system, for example, APEX1 T444G (solute carrier family 2, member 9) and ABCG2 &#13;
C421A RS2231142 (ATP-binding cassette, family G) are well-known genes for urate transporters &#13;
responsible for their reabsorption and excretion [13, 14, 27]. Thus, the determination of polymorphism &#13;
- APEX1 T444G and ABCG2 C421A RS2231142 genes can help in diagnosing the risk of developing &#13;
gout and optimizing the schemes of uricosuric therapy in patients with refractory gout.
</description>
<pubDate>Sat, 01 Jul 2023 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repo.tma.uz/xmlui/handle/1/5544</guid>
<dc:date>2023-07-01T00:00:00Z</dc:date>
</item>
<item>
<title>Clinical predictors of gene polymorphism in the occurrence of hyperuricemia and  gout</title>
<link>http://repo.tma.uz/xmlui/handle/1/5543</link>
<description>Clinical predictors of gene polymorphism in the occurrence of hyperuricemia and  gout
Elnora Djurayeva1., Masuda Kasimova1., Sevara Mukhamadiyeva1.,  Nigora Akhmedova1., Nargiza Abduazizova1
The article presents modern data on the influence of the most common &#13;
polymorphisms SLC2A9 and ABCG2 of genes encoding proteins that are involved in &#13;
the renal urate transport system and, thus, associated with the level of uric acid or &#13;
gout. Characterization of polymorphisms SLC2A9 and ABCG2 of genes: V253I, &#13;
Q126X, Q141K was carried out. It was determined that the GCA and GTC &#13;
haplotypes of the Q126X and Q141K polymorphisms can be predictors of gout. The &#13;
interrelation of SLC2A9 and ABCG2 gene polymorphisms with the presence of &#13;
hyperuricemia depending on gender, components of metabolic syndrome, and &#13;
response to allopurinol was analyzed. Most genes associated with MK or gout in a &#13;
genome-wide association study encode proteins that are involved in the renal urate &#13;
transport system, for example, SLC2A9 (solute carrier family 2, member 9) and &#13;
ABCG2 (ATP-binding cassette, family G) are well-known genes for urate &#13;
transporters responsible for their reabsorption and excretion. Thus, the determination &#13;
of polymorphism - SLC2A9 and ABCG2 genes can help in diagnosing the risk of &#13;
developing gout and optimizing the schemes of uricosuric therapy in patients with &#13;
refractory gout
</description>
<pubDate>Fri, 01 Jan 2021 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repo.tma.uz/xmlui/handle/1/5543</guid>
<dc:date>2021-01-01T00:00:00Z</dc:date>
</item>
<item>
<title>ОЦЕНКА УРОВНЯ ИНТЕРЛЕЙКИНА-1Β У ПАЦИЕНТОВ  С ПОДАГРОЙ В ЗАВИСИМОСТИ ОТ УРИКЕМИЧЕСКОГО  СТАТУСА И ТЯЖЕСТИ ЗАБОЛЕВАНИЯ</title>
<link>http://repo.tma.uz/xmlui/handle/1/5541</link>
<description>ОЦЕНКА УРОВНЯ ИНТЕРЛЕЙКИНА-1Β У ПАЦИЕНТОВ  С ПОДАГРОЙ В ЗАВИСИМОСТИ ОТ УРИКЕМИЧЕСКОГО  СТАТУСА И ТЯЖЕСТИ ЗАБОЛЕВАНИЯ
Джураева Э.Р., Зияева Ф.К., Каримов У.А
Цель исследования. Оценить уровень IL-1β у пациентов с подагрой в зависимости от урикемического статуса и тяжести заболевания.
</description>
<pubDate>Fri, 16 Oct 2026 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repo.tma.uz/xmlui/handle/1/5541</guid>
<dc:date>2026-10-16T00:00:00Z</dc:date>
</item>
<item>
<title>ОЦЕНКА ЧАСТОТЫ КОМОРБИДНОЙ  ПАТОЛОГИИ ПРИ ПОДАГРЕ</title>
<link>http://repo.tma.uz/xmlui/handle/1/5539</link>
<description>ОЦЕНКА ЧАСТОТЫ КОМОРБИДНОЙ  ПАТОЛОГИИ ПРИ ПОДАГРЕ
Джураева Э.Р., Зияева Ф.К., Ганиева Н.А.,  Шерипбаев Х.К
Цель исследования. Оценить частоту и структуру коморбидной патологии у больных подагрой
</description>
<pubDate>Thu, 16 Apr 2026 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repo.tma.uz/xmlui/handle/1/5539</guid>
<dc:date>2026-04-16T00:00:00Z</dc:date>
</item>
</channel>
</rss>
